Concomitant inhibition of Bcl-xL and Mcl-1 expression by RNA interference as a novel strategy for the treatment of ovarian carcinomas

被引：0
|
作者：
Denoyelle, C. [1 ]
Brotin, E. [1 ]
Duval, R. [1 ]
Simonin, K. [1 ]
Meryet-Figuiere, M. [1 ]
N'Diaye, M. [1 ]
Louis, M. H. [1 ]
Dutoit, S. [1 ]
Gauduchon, P. [1 ]
Poulain, L. [1 ]
机构：
[1] Ctr Francois Baclesse, F-14021 Caen, France
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 09期
关键词：
D O I：
10.1016/S1359-6349(08)71490-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：81 / 82
页数：2
相关论文
共 50 条
  • [21] Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
    Shang, Enyuan
    Nguyen, Trang T. T.
    Shu, Chang
    Westhoff, Mike-Andrew
    Karpel-Massler, Georg
    Siegelin, Markus D.
    CANCERS, 2020, 12 (08) : 1 - 21
  • [22] Cyclic Marinopyrrole Derivatives as Disruptors of Mcl-1 and Bcl-xL Binding to Bim
    Cheng, Chunwei
    Liu, Yan
    Balasis, Maria E.
    Simmons, Nicholas L.
    Li, Jerry
    Song, Hao
    Pan, Lili
    Qin, Yong
    Nicolaou, K. C.
    Sebti, Said M.
    Li, Rongshi
    MARINE DRUGS, 2014, 12 (03): : 1335 - 1348
  • [23] Pro-apoptotic meiogynin A derivatives that target Bcl-xL and Mcl-1
    Desrat, Sandy
    Pujals, Anais
    Colas, Claire
    Dardenne, Jeremy
    Geny, Charlotte
    Favre, Loetitia
    Dumontet, Vincent
    Iorga, Bogdan I.
    Litaudon, Marc
    Raphael, Martine
    Wiels, Joelle
    Roussi, Fanny
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (21) : 5086 - 5088
  • [24] The role of Mcl-1 and Bcl-xL in homeostasis and function of murine mast cells
    Foerster, A.
    Rabenhorst, A.
    Bouillet, P.
    Strasser, A.
    He, Y.
    Roers, A.
    Hartmann, K.
    EXPERIMENTAL DERMATOLOGY, 2014, 23 (03) : E8 - E8
  • [25] The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition
    Peddaboina, Chander
    Jupiter, Daniel
    Fletcher, Steven
    Yap, Jeremy L.
    Rai, Arun
    Tobin, Richard P.
    Jiang, Weihua
    Rascoe, Philip
    Rogers, M. Karen Newell
    Smythe, W. Roy
    Cao, Xiaobo
    BMC CANCER, 2012, 12
  • [26] The expression of antiapoptotic proteins Bcl-2, Bcl-XL, and Mcl-1 in benign, dysplastic, and malignant biliary epithelium
    Okaro, AC
    Deery, AR
    Hutchins, RR
    Davidson, BR
    JOURNAL OF CLINICAL PATHOLOGY, 2001, 54 (12) : 927 - 932
  • [27] Characterization of BCL-XL, MCL-1, and BAX Protein Expression in Response to Neoadjuvant Chemotherapy in Breast Cancer
    Saleh, Tareq
    Al Shboul, Sofian
    Awad, Heyam
    El-Sadoni, Mohammed
    Alhesa, Ahmad
    Alsharaiah, Elham
    Abu Shahin, Nisreen
    Alotaibi, Moureq R.
    Battah, AbdelKader
    Azab, Bilal
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2024, 32 (04) : 189 - 199
  • [28] The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition
    Chander Peddaboina
    Daniel Jupiter
    Steven Fletcher
    Jeremy L Yap
    Arun Rai
    Richard P Tobin
    Weihua Jiang
    Philip Rascoe
    M Karen Newell Rogers
    W Roy Smythe
    Xiaobo Cao
    BMC Cancer, 12
  • [29] Combined inhibition of Bcl-2 and MCL-1 in small cell lung cancer (SCLC) is most effective in tumors with low Bcl-xL expression
    Drapkin, Benjamin J.
    Sanghavi, Sneha
    Myers, David T.
    Zhong, Jun
    Phat, Sarah
    Wang, Youzhen
    Halilovic, Ensar
    Golji, Javad
    Farago, Anna
    Morris, Erick
    Dyson, Nicholas J.
    CANCER RESEARCH, 2019, 79 (13)
  • [30] mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1
    Coffee, Erin M.
    Faber, Anthony C.
    Costa, Carlotta
    Dastur, Anahita
    Ebi, Hiromichi
    Hata, Aaron N.
    Yeo, Alan T.
    Elena, J.
    Song, Youngchul
    Tam, Ah Ting
    Boisvert, Jessica L.
    Milano, Randy J.
    Roper, Jatin
    Kodack, David P.
    Jain, Rakesh K.
    Corcoran, Ryan B.
    Rivera, Miguel N.
    Ramaswamy, Sridhar
    Hung, Kenneth E.
    Benes, Cyril H.
    Engelman, Jeffrey A.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
12345